2007/05/01 by Timothy R. Smith, Timothy Smith, Harvey J. Blumenthal +9
Medicine · Neuroscience · #Migraine and Headache Studies #Neurological Complications and Syndromes #Vestibular and auditory disorders
paper · doi:10.1111/j.1526-4610.2007.00790.x
crossref issued 2007/05/01 · crossref published 2007/05/01 · crossref published-print 2007/05/01 · openalex publication_date 2007/05/01 · crossref published-online 2007/05/09 · crossref created 2007/05/10 · openalex created_date 2025/10/10 · crossref deposited 2025/11/02 · crossref indexed 2026/07/29 · openalex updated_date 2026/07/30
OBJECTIVE: To describe the pain relief, satisfaction, and health-related quality of life results of moderate or severe migraines treated with a sumatriptan/naproxen sodium combination tablet. METHODS: Sumatriptan and naproxen sodium as a single-dose formulation tablet was used to treat moderate to severe migraines over a 12-month period in a phase 3, open-label, multicenter study (n = 565) in patients with at least 6 months' history of migraine headaches. RESULTS: Seventy percent of all attacks were treated with 1 dose of sumatriptan/naproxen sodium. Overall subjects treated 24,485 attacks; of these, 81% attacks achieved pain relief and 60% pain-free by 2 hours. At 3 months, the percentage of patients satisfied or very satisfied increased from baseline on all 8 Patient Perception of Migraine Questionnaire (PPMQ) items and remained high throughout the study. Mean Migraine-Specific Quality of Life Questionnaire (MSQ) domain scores also increased by 13-15 points from baseline during this time and remained high. CONCLUSIONS: Sumatriptan/naproxen sodium provides consistent relief of migraine attacks over 12 months, resulting in improved patient satisfaction and migraine specific quality of life.